Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy-Reference-Cited by-同舟云学术

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy

Published:2020-08-04 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Bruera Gemma,D'Andrilli Antonio,Simmaco Maurizio,Guadagni Stefano,Rendina Erino Angelo,Ricevuto Enrico

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference51 articles.

1. “Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study;Bruera;BMC Cancer,2010

2. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy;Bruera;Expert Opin Biol Ther.,2011

3. Effectiveness of liver metastasectomies in metastatic colorectal cancer (MCRC) patients treated with triplet chemotherapy plus bevacizumab (FIr-B/FOx);Bruera;Clin Colorectal Cancer.,2012

4. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy;Bruera;Oncotarget.,2018

5. Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers;Bruera;Ther Adv Med Oncol.,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Forkhead-box A3 (FOXA3) Represses Cancer Stemness and Partially Potentiates Chemosensitivity by Targeting Metastasis-Associated in Colon Cancer 1 (MACC1) Signaling Pathway in Colorectal Cancer Cells;Current Cancer Drug Targets;2021-04-26

2. Breakthrough in targeted therapy for non-small cell lung cancer;Biomedicine & Pharmacotherapy;2021-01

3. Antineoplastics;Reactions Weekly;2020-10